Clinical Trials

Our programs focus on innovations that have the potential to deliver highly impactful
therapies for unmet medical needs and drive differentiated therapeutic benefits for patients Our programs focus on innovations that have the potential to deliver highly impactful therapies for unmet medical needs.

Phase 1/2a clinical trial of VK-2019 an oral EBNA-1 targeting agent in patients with Epstein-Barr Virus (EBV) -positive recurrent or metastatic Nasopharyngeal (NPC). Status: Recruiting
Study ID: NCT03682055
LEARN MORE
Phase 1/2a open label, multi-center study of CLN-081 in patients with NSCLC (non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations. Status: Not yet recruiting
Study ID: NCT04036682
LEARN MORE